Jazz Pharmaceuticals plc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Renee D. Gala
- Full Time Employees
- 2,890
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Waterloo Exchange Dublin DU Ireland D04 E5W7
- IPO Date
- Jun 1, 2007
- CIK
- 0001232524
- Website
- jazzpharma.com
- Similar Companies
- Business
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ), headquartered in Dublin, Ireland and founded in 2003, develops and commercializes innovative biopharmaceutical products for serious diseases with significant unmet needs, primarily in neuroscience and oncology; its core portfolio includes Xywav and Xyrem (sodium oxybate formulations) for cataplexy and excessive daytime sleepiness in narcolepsy, Epidiolex (cannabidiol oral solution) for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, Defitelio (defibrotide) for severe hepatic veno-occlusive disease post-hematopoietic stem-cell transplantation, Rylaze (asparaginase erwinia chrysanthemi recombinant) for acute lymphoblastic leukemia, Vyxeos (daunorubicin and cytarabine liposome injection) for therapy-related acute myeloid leukemia and newly diagnosed acute myeloid leukemia, Zepzelca (lurbinectedin) for metastatic small cell lung cancer, Modeyso (vosoritide) for achondroplasia in pediatric patients, and Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer; products are marketed in nearly 75 countries across North America, Europe, and select international markets including Australia, Israel, Japan, Canada, and parts of the Middle East and Latin America. Recent developments include FDA approval of Ziihera (zanidatamab-hrii) in November 2024 for biliary tract cancer with ongoing pursuits in HER2-positive breast cancer, a March 2025 definitive agreement to acquire Chimerix for approximately $935 million to bolster its pipeline, an August 2025 exclusive licensing agreement with Saniona for SAN2355 targeting epilepsy and neurological conditions where Jazz leads global development and commercialization, a February 2024 deal with Redx Pharma acquiring global rights to a KRAS inhibitor program for up to $880 million, and a October 2025 research collaboration with Iambic Therapeutics on AI-driven drug discovery. The company maintains manufacturing facilities in Ireland, England and Italy, with significant operations in Palo Alto, Philadelphia, Oxford and Cambridge.
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
JAZZ vs. TECH: Which Stock Is the Better Value Option?
Jazz Pharmaceuticals' Re-Rating Story Has Legs
Jazz Pharmaceuticals PLC $JAZZ Stake Boosted by Bank of America Corp DE
Jazz Pharmaceuticals Q2 Earnings Call Highlights
Amundi Acquires 53,454 Shares of Jazz Pharmaceuticals PLC $JAZZ
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results
Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript
Compared to Estimates, Jazz (JAZZ) Q2 Earnings: A Look at Key Metrics
Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimates
Jazz Pharmaceuticals Q2 Earnings Call Highlights
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
Aristotle Global Equity Advisory Q2 2026 Portfolio Review
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term